Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* locally advanced stage III or IV squamous cell carcinoma of the larynx, oropharynx, or hypopharynx~* ≥18 years old~* absolute neutrophil count ≥1,500/µL, platelets ≥100,000/µL~* serum bilirubin \<2.0 mg/dL~* creatinine \<1.5 mg/dL~* serum transaminase levels less than twice the upper limit of normal~Exclusion Criteria:~* received previous chemotherapy~* another malignancy~* current or history of distant metastasis~* history of clinically significant cardiac disease within 6 months~* active serious infection~* nasopharyngeal carcinoma~* psychiatric illness that would preclude obtaining informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-1, induction chemotherapy (Type: EXPERIMENTAL): Cisplatin and 5-FU is the standard treatment for patients with head and neck cancer. Recently,docetaxel was used into CF, and it showed the prolongation of survival. Oral 5-FU showed similar or enhanced response rate, safety than intravenous 5-FU. S-1 showed promising preliminary result in combination with cisplatin in head and neck cancer. In patients with gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid, 60mg/m2 (D1) and 60mg/m2 (D1), respectively. And weekly docetaxel can reduce adverse events compared to 3 week regimen. The aim of this study was to evaluate the efficacy and safety of weekly docetaxel, cisplatin and S-1 combination chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).